05:29 PM EDT, 03/26/2026 (MT Newswires) -- Disc Medicine ( IRON ) said late Thursday the last participant was randomized and dosed in the phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria.

The study was expanded to 183 participants from 150 due to patient and physician demand, the company said.

Bitopertin is an investigational, clinical-stage, orally administered inhibitor of glycine transporter 1, designed to modulate heme biosynthesis, the company noted.